Erlocent 100 mg (Tablet)
Unit Price: ৳ 550.00 (1 x 10: ৳ 5,500.00)
Strip Price: ৳ 5,500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Erlotinib |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- First-line treatment of patients with metastatic Non-Small Cell Lung cancer (NSCLC)
- Maintenance treatment of patients with locally advanced or metastatic NSCLC
- Treatment of locally advanced or metastatic pancreatic cancer
Description
Erlocent is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine. Erlocent reversibly inhibits the kinase activity of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor and thereby inhibiting further downstream signaling.
Dosage & Administration
- Recommended daily dose for NSCLC is 150 mg taken on an empty stomach
- Recommended daily dose for pancreatic cancer is 100 mg taken once daily in combination with gemcitabine
Interaction
- Interaction with coumarin-derived anticoagulants leading to increased International Normalized Ratio (INR) and bleeding
- Metabolized predominantly by CYP3A4. Co-treatment with the potent CYP3A4 inhibitor ketoconazole increased Erlocent AUC by 67%
- Pre-treatment with the CYP3A4 inducer Rifampicin for 7-11 days prior to Erlocent decreased Erlocent AUC by 58% to 80%
Side Effects
- Common adverse reactions include rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting
- Serious adverse reactions may include Interstitial Lung Disease (ILD), Gastrointestinal Perforation, and Myocardial Infarction/Ischemia
Pregnancy & Lactation
Pregnancy category D. Erlotinib can cause fetal harm when administered to a pregnant woman
Precautions & Warnings
- Withhold Erlocent for acute onset of new or progressive unexplained pulmonary symptoms, such as dyspnea, cough and fever
- Monitor periodic liver testing. Withhold or discontinue Erlocent for severe or worsening liver tests
Use in Special Populations
- The safety and effectiveness of Erlocent in pediatric patients have not been established
- No overall differences in safety or efficacy were observed between subjects 65 years and older and those younger than 65
Overdose Effects
Repeated twice-daily doses of 200 mg single-agent Erlocent in healthy subjects were poorly tolerated after only a few days of dosing. In case of suspected overdose, Erlocent should be withheld and symptomatic treatment instituted
Therapeutic Class
Targeted Cancer Therapy
Storage Conditions
Store at a temperature not exceeding 30°C in a dry place. Protect from light and moisture